When the Gap Between the Deck and the Reality IS the Story

I've read a lot of company materials over the years. But if there’s one pattern I’ve learned to pay attention to, it’s the distance between what a company presents and what actually exists beneath the surface.

Pitch decks, one-pagers, strategic plans, clinical overviews, competitive landscapes, go-to-market frameworks. Hundreds of them, across different stages, geographies, and therapeutic areas. And after a while, you develop a kind of fluency - not just in what the materials say, but in what the gap between the materials and the reality is telling you.

Because there is almost always a gap.

That's not a criticism. It's the nature of strategic communication - you present the best version of the story. The question is how wide the gap is, and what kind of gap it is.

Some gaps are honest. The company is early, the data is preliminary, the market is unproven -and the materials reflect that with appropriate nuance. These companies are usually easier to work with, because the conversation can be honest from the first meeting.

Other gaps are structural. And those are the ones worth paying attention to.

The companies I've seen handle this well share something in common. Their leadership teams are unusually honest about what they don't yet know. 

A structural gap is when the commercial narrative doesn't reflect how the commercial team actually thinks. When the competitive slide lists three competitors that every informed person in the room knows is an incomplete picture. When the market sizing is confident and the unit economics are vague. When the leadership slide describes a full team and the operational reality is four people carrying everything.

None of these are dealbreakers on their own. But they're patterns. And patterns, in my experience, travel.

A company that is selective about its rigor in the investor presentation is usually selective about its rigor elsewhere. The same logic that said "this slide is good enough" is usually the same logic making other calls - about pricing strategy, distributor selection, clinical trial design, or how resources get allocated when money is tight.

What I find most interesting is that the gap is rarely the result of bad intention. Most of the time, it comes from something more human: the distance between how a company sees itself and what it has actually built.

This gap is almost universal in early-to-mid-stage companies. The vision is real, the belief is genuine, and the internal narrative, the one the leadership team tells itself, is often several steps ahead of the external evidence.

That's not a character flaw. Founders need that belief to keep going. But it becomes a problem when the gap is invisible to them, when they can no longer see the distance between the internal story and the external reality, because they've been living inside the internal story for so long.

As someone who has worked across marketing, commercial strategy, and business development for a long time, and who has spent years at the intersection of investor-readiness and company assessment, I've come to think that the most valuable thing an outside perspective can offer is not validation or critique.

It's calibration.

The ability to say: here is what you've built. Here is what you're claiming. Here is the distance between them. And here - specifically - is where you need to close that gap before the market closes it for you.

Because the market will close it. Investors close it. Distributors close it. Hospital procurement teams close it. And the way that closure happens externally is almost always more disruptive than the way it could have happened internally, with time and honest intention.

The companies I've seen handle this well share something in common.

Their leadership teams are unusually honest about what they don't yet know. They hold the vision with conviction but hold the current evidence with appropriate humility. They use the gap not as something to hide but as something to map, because a clearly mapped gap is a roadmap, and a hidden gap is a risk.

That quality - the willingness to see clearly - turns out to be one of the most commercially important things a company can have.

Not because investors reward honesty as a virtue. But because companies that see themselves clearly make better decisions. They allocate resources better. They hire better. They choose their partners better. They know what they need before they need it.

The deck is never just a deck. It's a window into how a company thinks about itself.

And what you see through that window, the consistency or inconsistency between the story and the substance, tells you most of what you need to know about what it will be like to work with them when the story gets complicated.

Which it always does, eventually.

---

A global healthcare strategist, Moran Faibish brings extensive experience in commercialization, fundraising, corporate strategy, and business development across the life sciences industry. She is the CEO of Ela Pharma and the co-founder of DDS, a company assessment methodology for investors and healthcare companies built on three dimensions: scientific validation, commercial feasibility, and human capital.